China+1 opens larger share for India in global pharma manufacturing beyond generics: BCG report

New Delhi:  India is poised to capture a bigger share of the global pharmaceutical manufacturing market beyond generics, according to a report by Boston Consulting Group (BCG).

The report highlighted that the “China+1” strategy, which involves companies diversifying operations beyond China, has opened doors for other Asian countries, including India. This shift is driving investments into India’s pharma sector, enabling it to expand beyond its traditional focus on generic drugs.

“India to capture a larger share of global pharma manufacturing, expanding beyond generics… As pharmaceutical companies look to diversify their investments and manufacturing operations beyond China, Indian players are capitalizing on this opportunity,” the report read.

As pharmaceutical companies look to reduce reliance on China, India is emerging as a key player in the global supply chain. Indian pharmaceutical services are 20 per cent cheaper than those offered by China, making the country an attractive destination for manufacturing operations.

The report also identified four major sectors for healthcare investments: health services, pharmaceuticals and biotechnology, digital health, and MedTech.

Of the total investments, USD 9.5 billion has been allocated to pharmaceuticals and biotechnology, while health services have received USD 12.1 billion. Digital health has experienced remarkable growth, securing USD 4.6 billion in investments, with USD 3.8 billion of that amount flowing in over the last five years.

The report also mentioned that Singapore and India have emerged as leading hubs for healthcare innovation and investment in the region, attracting significant funding and playing pivotal roles in transforming the sector. Since 2018, private equity investments in Asia’s pharma and biotech sectors have totalled USD 20 billion, with India receiving USD 5 billion.

The report outlined that Asia’s healthcare market is projected to reach USD 5 trillion by 2030, contributing 40 per cent of global sector growth.

The report underlined that Asia’s developing economies are positioned for significant economic benefits as they continue to invest in healthcare. It offers a detailed analysis of the market from the perspectives of providers, innovators, and payers, identifying key drivers of transformation across the region.

India’s competitive pricing and growing infrastructure place it at the forefront of this shift, signalling promising growth for the country’s pharmaceutical and healthcare sectors.

Related Posts

  • Pharma
  • February 3, 2025
  • 13 views
Smuggler Apprehended With 62,000 Narcotic Capsules And 6,600 Tablets Valued At 1.5 Million In Saharanpur

Saharanpur: Concerns are once again being raised regarding the operational effectiveness of the FSDA in Saharanpur. The district is witnessing the distribution of not only heroin but also various narcotic drugs…

  • Pharma
  • February 3, 2025
  • 48 views
With The Customs Duty Exemption, Prices Could Drop By Rs 10,000 To Rs 30,000 Per Dose

New Delhi:  In a significant move to reduce the financial burden on patients battling life-threatening diseases, Finance Minister Nirmala Sitharaman announced a full exemption from basic customs duty on several…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Smuggler Apprehended With 62,000 Narcotic Capsules And 6,600 Tablets Valued At 1.5 Million In Saharanpur

Smuggler Apprehended With 62,000 Narcotic Capsules And 6,600 Tablets Valued At 1.5 Million In Saharanpur

With The Customs Duty Exemption, Prices Could Drop By Rs 10,000 To Rs 30,000 Per Dose

With The Customs Duty Exemption, Prices Could Drop By Rs 10,000 To Rs 30,000 Per Dose

2880 Anti-Rabies Vaccine Vials Stolen From Manihari Hospital; Suspect Arrested

2880 Anti-Rabies Vaccine Vials Stolen From Manihari Hospital; Suspect Arrested

Union Budget 2025 pleased Healthcare Leaders except for a Letdown or two

Union Budget 2025 pleased Healthcare Leaders except for a Letdown or two